FDA Brief

Warning letters Drugs

FDA warning letter to

Verdure Sciences, Inc.

High riskIssued Nov 10, 2025Posted Nov 18, 2025Center for Drug Evaluation and Research (CDER)

FDA says Verdure Sciences ran a clinical trial of Maplifa without submitting a required IND.

What happened

FDA inspected Verdure from June 25 to July 12, 2024, as part of its Bioresearch Monitoring Program. FDA reviewed Protocol 005, a randomized, double-blind study of topical Maplifa (1% or 5%) for facial wrinkles, redness, and pigmentation, and found Verdure began the study without submitting and having an IND in effect. FDA rejected Verdure's arguments that Maplifa was cosmetic-only, that a proposed rule exempted it, and that a contract research organization had taken over sponsor duties.

What FDA found

  1. Verdure started Protocol 005, a clinical trial of Maplifa in people, before submitting an IND and having it in effect.

    21 CFR 312.20(a), 312.20(b), 312.40(a)
  2. FDA concluded Maplifa was being studied as a drug because the trial measured effects on wrinkles, redness, brightness, erythema, and hyperpigmentation.

    FD&C Act section 201(g)(1) [21 U.S.C. 321(g)(1)]
  3. FDA found the study did not meet the IND exemption because Maplifa was not lawfully marketed as a drug and the proposed rule Verdure cited was not final.

    21 CFR 312.2(b)(1)
  4. Verdure's contract with the third-party vendor did not describe which sponsor duties, if any, were transferred.

    21 CFR 312.52; 21 CFR 312.3
  5. Verdure's response did not give enough detail about procedures to ensure future IND compliance.

What FDA wants

Within 15 business days of receiving the letter, Verdure must tell FDA in writing what actions it has taken to prevent similar violations and establish procedures for future studies. If it believes it complied, it must include reasoning and supporting information.

Who should pay attention

  • clinical trial sponsors
  • contract research organizations
  • IRBs and study sites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  3. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  4. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk